EN | UA
EN | UA

Help Support

Back

Delphi Consensus: Brivaracetam as first add-on therapy for focal epilepsy

Focal epilepsy Focal epilepsy
Focal epilepsy Focal epilepsy

What's new?

Backed by its pharmacological profile and real-world efficacy, Brivaracetam emerges as a favourable first add-on treatment for epilepsy, although caution is advised for use in pregnancy and among young women of childbearing age.

Picking the best of the best! Brivaracetam, a third-generation anti-seizure medication, has emerged as a potential early add-on therapy for elderly populations.

Selecting the most effective medications for patients is critical, particularly when standard therapies fail to provide adequate seizure control. A recent Delphi consensus exercise, published in the Neurological Sciences journal was executed to outline the role of brivaracetam in providing essential guidance for clinicians in daily practice. Through a rigorous review of the literature and collaborative voting, the panel crafted 15 consensus statements, all unanimously endorsed in the initial round of voting.

Brivaracetam was known to have encouraging attributes, making it a viable choice for individuals with focal epilepsy, including the elderly and those with post-stroke epilepsy or status epilepticus. Notable characteristics include rapid action, minimal drug interactions, broad-spectrum efficacy, and good tolerability across various dosage ranges. Importantly, the medication has shown sustained clinical response and long-term tolerability, further solidifying its position as a valuable addition to the epilepsy treatment arsenal.

Source:

Neurological Sciences

Article:

Brivaracetam use in clinical practice: a Delphi consensus on its role as first add-on therapy in focal epilepsy and beyond

Authors:

Simona Lattanzi et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru ua
Try: